Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pope Research Corporation
With
Amgen
Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score \<2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Psoriatic Arthritis as diagnosed by a rheumatologist and meeting ACR classification criteria for PsA or CASPAR criteria
The subject must provide written informed consent for participation in the study before any study specific procedures are performed
Subject has 3 or more SJC on 28 joint count
Age \>=18
You may not be if
Subject has a history of being non-compliant
Serious concomitant illnesses that in the investigator's opinion negate ability to optimally treat the patient
If treating with TNF inhibitor, positive PPD \> 5mm who have not received INH for recommended course or untreated TB (ie CXR evidence of latent infection). Usual screening is in place for standard of care.
Pregnancy, breast-feeding or considering pregnancy over the next 12 months
Clareo Health | Psoriatic Arthritis Treat to Target vs. Usual Care
